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Insights into the role of the beta-2 microglobulin
D-strand in amyloid propensity revealed by mass
spectrometry†
Aneika C. Leney,‡ Clare L. Pashley, Charlotte A. Scarff, Sheena E. Radford* and
Alison E. Ashcroft*
In vivo beta-2 microglobulin (b2m) forms amyloid fibrils that are associated with the disease dialysis-related
amyloidosis. Here, electrospray ionisation-ion mobility spectrometry-mass spectrometry has been used to
compare the oligomers formed from wild-type b2m with those formed from a variant of the protein
containing a single point mutation in the D strand, H51A, during in vitro fibril assembly. Using the amyloid-
binding fluorescent dye, Thioflavin T, to monitor fibrillation kinetics, H51A was shown to exhibit a two-fold
increase in the lag-time of fibril formation. Despite this, comparison of the oligomeric species observed
during the lag-time of self-aggregation indicated that H51A had a higher population of oligomers, and
formed oligomers of higher order, than wild-type b2m. The cross-sectional areas of the oligomers arising
from H51A and wild-type protein were indistinguishable, although the H51A oligomers were shown to have
a significantly higher kinetic stability on account of their reluctance to undergo sub-unit exchange when
mixed with 15N-labelled protein. Together the data reveal a significant effect of His51, and thus that of the
D-strand sequence, on amyloid formation. The results also highlight the power of mass spectrometry in
probing complex biochemical mechanisms in real-time.
Introduction
The correct folding of proteins into their native, functional states
is highly dependent on protein sequence, the environment, and
the presence of additional factors including chaperones.1,2 If the
balance of these conditions is altered, protein misfolding and/or
aggregation can occur resulting in some cases in long, straight,
unbranched polymeric structures with a characteristic cross-b struc-
ture, termed amyloid.3,4 Here, we focus on the amyloid-forming
protein beta-2 microglobulin (b2m) whose aggregation in humans
is the primary causative agent of the disease dialysis-related
amyloidosis.5,6 b2m is the non-covalently bound light chain of
the major histocompatibility complex class 1 (MHC 1) and in
healthy subjects is excreted through the kidneys after dissociation
from the MHC 1. In patients undergoing dialysis, this excretion
pathway is unavailable and b2m protein levels in the body rise,
resulting eventually in their self-aggregation into amyloid fibrils.
b2m is a 99-residue, B12 kDa protein. In its native state,
b2m consists of seven b-strands (A–G) arranged as two b-sheets
involving the b-strands ABED and CFG in a b-sandwich fold
connected by a disulphide bond between residues Cys25 and
Cys80 (Fig. 1A).7 In vitro b2m remains soluble at pH 7.5 with no
evidence of amyloid formation even after 100 days of incubation
at 37 1C.8–10 However, insoluble amyloid fibrils do form in hours
to days in vitro, dependent on the precise solution conditions
and agitation rate, in low ionic strength (o100 mM) buffer at
pH 2.5.11–13 In this environment, the highly dynamic acid-unfolded
b2mprotein self-aggregates into long, straight, unbranched, twisted
fibrils displaying all the hallmarks of amyloid.13–18 Thus, the time-
scale of these experiments is ideally suited for model investigations
into the self-aggregation process.
Electrospray ionisation-mass spectrometry and its combi-
nation with ion mobility spectrometry (ESI-IMS-MS) have led to
significant advances in the understanding of the mechanism of
amyloid fibril formation, in particular concerning the specific
oligomeric intermediates formed during self-aggregation.19,20
The study of these transient oligomers is particularly important as
their presence correlates well with amyloid disease progression21–23
and, furthermore, it has been suggested that these oligomers may
well be the toxic species rather than the fibril end-products.24–26
Previous ESI-IMS-MS analyses have enabled the identification
and separation of co-populated, non-covalently bound b2m
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oligomers based on their charge, shape and mass from within
the highly heterogeneous mixtures present during amyloid
formation.27,28 ESI-IMS-MS rotationally averaged collision
cross-sectional area (CCS) estimations of the b2m oligomers
formed at pH 2.5 have suggested that these species adopt a stacked
conformation of end-to-end b2m monomers rather than an alter-
native, more compact, globular arrangement.27
The current study utilises ESI-IMS-MS, in parallel with muta-
genesis and biochemical techniques, to focus on understanding
the eﬀect of the amino acid sequence comprising the native D
b-strand of b2mon fibrillogenesis, a region which is known to form
important structural contacts with the a-chain of the MHC 1.29
Interestingly, on release from the MHC 1, this b-strand becomes
highly dynamic30 and is known to be aggregation prone,31 suggest-
ing a key role for the D-strand sequence in the self-aggregation of the
protein monomer.9,29,32 The D-strand of b2m is involved in the non-
covalent binding of b2m to the heavy chain of the MHC 1 (Fig. 1).
Available crystal structures show a bulged D-strand in complex with
the heavy chain of the MHC 1 (Fig. 1B and D) with residue Asp53
(the b-bulge residue at the centre of the D-strand sequence)
hydrogen-bonded to Arg35 on the heavy chain of the MHC 1.35
On dissociation from the MHC 1 complex, the D-strand
becomes solvent exposed and thus may be involved in initiating
b2m aggregation. Indeed, X-ray crystallography and NMR stu-
dies have indicated that the D-strand is highly dynamic,
adopting multiple conformations in solution7,29,36–38 with
molecular dynamic simulations showing a straight D-strand
to be populated on decreasing pH.39 Although the exact b2m
oligomeric structure at low pH still remains to be elucidated,
experiments involving covalent labelling combined with mass
spectrometry have suggested a role of the D-strand sequence in
the oligomeric interface of the b2m dimer and tetramer at neutral
pH in the presence of Cu2+.40,41 Mutations in the D-strand of b2m
have been shown previously to alter the lag-time of fibril for-
mation at pH 2.5 suggesting that the D-strand sequence may play
a role in fibrillogenesis.33,42 A single point mutation, H51A, in
particular, has been shown to increase the lag-time of fibrillo-
genesis in vitro by up to two-fold, even though the eventual fibril
morphology, as judged by negative stain electron microscopy
(EM), remained comparable with that of the WT b2m protein.
33
Interestingly, on transition of the D-strand from the bent to the
straight conformation (Fig. 1), His51 rotates through 1801 and is
no longer involved in H-bonding to Tyr66 (Fig. 1C and D). Thus,
substitution of residue 51 to alanine is thought to cause slight
structural perturbations in the D-strand conformation which
result in the increased lag-time of amyloid formation observed.
Here, oligomers originating from wild-type (WT) b2m under
in vitro fibril-forming conditions have been compared with
oligomers formed from H51A, the construct resulting from a
single point mutation within the D-strand of the WT sequence.
Despite both proteins self-aggregating into fibrils of very similar
morphology, the lag-times of assembly are diﬀerent. Furthermore,
the shape (in terms of CCS), population and dynamics of the
oligomers observed during fibril formation have been investigated
to provide insights into the role of the sequence that comprises
the D-strand of b2m in the amyloid assembly process.
Materials and methods
Reagents
Ammonium formate and thioflavin T (ThT) were purchased from
Sigma-Aldrich (Gillingham, Dorset, UK). 14NWT b2m,
14NH51A and
15Nwild-type (WT) b2mwere prepared as described previously.
33 15N
H51A was expressed in 15N-enriched minimal media and purified
as described.33 All proteins were determined to be monomeric by
gel filtration, shown to be pure by SDS-PAGE analysis, and their
molecular mass determined using ESI-MS. The molecular masses
for WT and H51A were accurate to within 0.01% of those predicted
based on amino acid composition (11860.3 Da and 11794.3 Da,
respectively). Protein concentrations were calculated from the A280
using the extinction coeﬃcient 20065 M1 cm1.
Formation of amyloid fibrils from b2m WT and H51A
b2m and H51A (0.4 mg mL
1) were incubated separately in
100 mM ammonium formate (pH 2.5; 37 1C) shaking at 600 rpm
Fig. 1 Ribbon structures of wild-type human b2m highlighting the differ-
ent conformations of the D strand (yellow) between (A) monomeric, apo-
b2m (PDB file: 1LDS)
7 and (B) the MHC 1-bound holo form (PDB file: 2X70).
The hydrogen bond contacts (black dashed lines) between the D- (yellow)
and E- (green) strands of b2m are shown in the case of both monomeric,
apo-b2m (C) and the MHC 1-bound holo form (D). The location of His51
(red) is highlighted on each structure.
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using a Thriller Thermoshaker Incubator (PEQLAB Ltd,
Southampton, UK). Fibril growth kinetics were monitored
using ThT fluorescence. 50 mL aliquots were removed at regular
intervals and diluted with 950 mL ThT (20 mM) in 100 mM
ammonium formate pH 2.5. ThT fluorescence was measured in
a PTI Quantamaster C-61 spectrofluorimeter using an excitation
wavelength of 444 nm and emission at 480 nm with slit-widths of
4.5 nm. At the end-point of the reaction, samples were taken for
negative stain transmission electron microscopy (EM). Simulta-
neous to the ThT reading, a 10 mL sample of the b2m variant in
100 mM ammonium formate pH 2.5 was removed separately for
mass spectrometric analysis. To ensure accuracy in lag-time esti-
mations of fibril formation between experiments, WT b2m was
analysed alongside the b2m variant H51A on each day of analysis.
The lag-time was obtained by fitting a tangent to the steepest part
of the normalised ThT growth phase and the time at which the line
intersected the baseline was taken as the lag-time.33,34 The average
fold change in lag-time compared with WT b2m is reported along
with the standard deviation between five replicates.
Fibril yield
b2m and H51A (0.4 mg mL
1) were incubated under the fibril
forming conditions described above. After 46 h, samples were
taken and the fibrils pelleted by centrifugation (13 000g, 30 min).
The supernatant in each case was analysed by SDS-PAGE along
with an identical sample taken prior to fibril formation.
Electron microscopy
10 ml of fibrils in 100 mM ammonium formate pH 2.5 (i.e., reaction
end products) were placed on freshly ionised formvar- and carbon-
coated EM grids for 30 s. The grids were then blotted with filter
paper to remove excess solvent and the samples stained with
2% (w/v) uranyl acetate for 30 s. The grids were blotted again and
air-dried before analysis. All images were taken using a CM10
electron microscope (Phillips Research, Eindoven, Netherlands)
operating at 80 keV.
ESI-IMS-MS
ESI-IMS-MS experiments were performed on a Synapt HDMS
hybrid quadrupole-IMS-oaTOF (Waters Ltd, Manchester, UK)
mass spectrometer interfaced with a NanoMate Triversa
nanoESI sample inlet and source (Advion Biosystems Inc.
Ithaca, NY, USA). Positive nanoESI was performed using a
capillary voltage of 1.75 kV and a nitrogen nebulising gas
pressure of 0.7 p.s.i. A cone voltage of 170 V and a backing
pressure of 3.6 mbar were used to observe the b2m oligomers.
The ion accelerating voltages into the trap and transfer T-wave
were set at 6 V and 20 V, respectively. The wave height was
ramped from 4–12.5 V with a speed of 300 m s1. For all mass
spectrometry experiments, CsI clusters were used to calibrate the
mass spectrometer and the raw data processed using MassLynx
v.4.1 software (Waters Ltd, Manchester, UK) in combination with
Driftscope v.3.0.
14N/15N-b2m oligomer exchange
For subunit exchange measurements carried out at 50% of
the lag-time of fibril growth, the lag-time was estimated (using
previously acquired data) and at the correct time-point during
fibril growth, 100 mL of the 14N b2mWT or
14N H51A was mixed
in a 1 : 1 v/v ratio with 100 mL of predominantly monomeric
15NWT b2m or
15N H51A (incubated on ice throughout the time
course), respectively. Mass spectra were acquired after 1 min
and 50 min of mixing. All samples were incubated in the 96-well
plate within the NanoMate Triversa device at 20 1C throughout
the subunit exchange experiments. The extent of subunit
exchange was determined by comparing the area under the
peaks corresponding to the 14N WT b2m/
14N H51A and the
15N WT b2m/
15N H51A oligomers analysed at t = 1 min with
the mixed 14N WT b2m:
15N WT b2m and
14N H51A:15N H51A
subunit exchanged oligomers, respectively.
Sedimentation velocity analytical ultracentrifugation
Sedimentation velocity experiments were carried out at 25 1C using
a Beckman Optima XL-I analytical ultracentrifuge (Beckman, Palo
Alto, CA) using an An-60 Ti rotor with conventional aluminium
double-sector centrepieces with a rotor speed of 40 000 rpm.
Samples (0.4 mg mL1) were prepared in the buﬀer used for MS
analyses by overnight dialysis 4 1C. Radial absorbance scans at
280 nm were collected at 300 s intervals and the data were
analysed using SEDFIT.43
Results and discussion
H51A increases the lag-time of in vitro fibril formation
compared with wild-type b2m
Here, ESI-MS was used to investigate the nature of the oligomers
formed during H51A fibril formation in order to probe how this
single point mutation retards the rate of amyloid formation at low
pH in vitro. To achieve this, fibril formation was performed inde-
pendently for both wild-type (WT) b2mandH51A by incubating each
protein at 37 1C with agitation (600 rpm) in 100 mM ammonium
formate at pH 2.5.27,33 Under these conditions, WT b2m and
H51A both form amyloid-like fibrils with lag-dependent kinetics,
as shown by ThT fluorescence (Fig. 2A). In each case, negative
stain EM analysis indicated that the fibrils produced exhibit
long, straight morphologies (Fig. 2B), similar to the architecture
of ex vivo fibrils. Consistent with previous results carried out
using non-volatile (i.e., MS-incompatible) buﬀers,33 the lag-time
of fibril formation is increased Btwo-fold for H51A compared
with WT b2m (Fig. 2A and C), thus supporting a potential role of
His51 in b2m amyloid fibril formation.
H51A populates higher order oligomers during the lag-time of
in vitro fibril assembly compared with wild-type b2m
ESI-MS and ESI-IMS-MS were used to investigate the populations
of, and any structural diﬀerences between, the oligomeric inter-
mediates formed by H51A and WT b2m during fibril assembly,
which may explain the diﬀerence in the kinetics observed and
reveal insights into the amyloid formation mechanism. On initial
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dilution of WT b2m into the fibril-forming buﬀer (100 mM
ammonium formate, pH 2.5 to give a final protein concen-
tration of 0.4 mg mL1), an aliquot was removed and analysed.
At the earliest time-point measurable (1 min) the ESI mass
spectrum was dominated by monomer ions (Fig. S1, ESI†)
together with low intensity dimer, trimer and tetramer ions (the
latter highlighted in Fig. 3A). In contrast, in addition to monomer,
higher order oligomers from dimer to pentamer, inclusively, were
observed at higher relative intensities in the ESI mass spectrum
upon dilution of H51A into the fibril-forming buﬀer (Fig. 3B,
Fig. S1, ESI†) suggesting that the H51A variant is significantly
more prone to form oligomers compared with WT b2m at low pH,
despite having a longer lag-time of fibril assembly.
The ESI-IMS-MS driftscope plots of WT b2m and the variant
H51A acquired on initial dilution into fibril-forming buﬀer
illustrate the added dimension of IMS in its ability to separate
oligomers of diﬀerent sizes including those ions of the same
m/z but of both diﬀerent mass and diﬀerent charge (Fig. 3C and D,
respectively). For both proteins, oligomers were separated
within these highly heterogeneous populations, allowing each
species to be assigned uniquely based on its m/z values and
charge states. With the extra separation dimension, at the
initial time-point at the start of the lag-phase oligomers up to
and including the pentamer could be detected for WT b2m (as
described previously27), and oligomers up to and including the
hexamer were observed for H51A (Fig. 3C and D, respectively).
Furthermore, the ESI-IMS-MS data show clearly that the higher
order oligomers are significantly more populated in the case of
H51A compared with WT b2m.
A control experiment was performed to compare the extent
of oligomerisation of WT b2m and H51A in solution and thus to
verify the legitimate presence of the oligomers observed by use
of gas-phase mass spectrometry analyses. Thus, solutions of
both proteins in the buﬀers used for the mass spectrometry
studies were subjected independently to sedimentation velocity
analysis (Fig. S2, ESI†). In both cases, protein monomer together
with a distribution of oligomers were observed. In agreement with
the mass spectrometry data, oligomers were found in solution
for both WT b2m and H51A, with the diﬀerence in peak widths
of the distribution of species found suggestive of diﬀerent rates
of interconversion between diﬀerent oligomeric forms for H51A
compared with WT b2m. These results are consistent with our
previous WT b2m studies in which protein aggregates observed
in the gas-phase were shown to reflect the oligomers detected
in solution using a similar analysis.44
To monitor the progression of self-assembly and fibril for-
mation, WT b2m and H51A were incubated separately at 37 1C in
100 mM ammonium formate, pH 2.5, with agitation at 600 rpm.
At various time-points, aliquots were removed for ESI-IMS-MS
analysis, with simultaneous ThT fluorescence analysis to confirm
the duration of the lag-phase of fibril formation. The ESI-IMS-MS
data for WT b2m and H51A at 50% of their individual lag-phases
of fibril formation are shown in Fig. 3E and F, respectively.
These data indicate that the population of oligomeric species
Fig. 2 (A) Graph showing ThT kinetics of fibril formation for WT b2m (black) and H51A (grey); one trace from five replicates is shown for each for
simplicity. (B) Electron microscopy images of fibrils formed in 100 mM ammonium formate pH 2.5, 37 1C, 600 rpm, from WT b2m and the b2m variant
H51A; the scale bar in each case represents 200 nm. (C) Fold change in lag-time of H51A compared with WT b2m; the average of five replicates is shown
together with the standard deviation between replicates. (D) Final H51A ThT fluorescence signal expressed as a percentage of the WT b2m final ThT
fluorescence signal; the average and standard deviation between five replicates is shown. (E) SDS-PAGE analysis of WT b2m (lane 1) and H51A (lane 3)
prior to fibril formation compared with the remaining soluble fractions post-fibril formation (lanes 2 and 4 for WT b2m and H51A, respectively).
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for the WT protein decreases during the lag-phase, with ions
corresponding to the 12+ to 16+ charge states of the pentamer
no longer being observed. This suggests that the higher order
oligomers observed at the start of fibril formation have
extended rapidly into pre-fibrillar species and/or into amyloid
fibrils that are undetectable using ESI-IMS-MS analysis alone.
By the end of the lag-phase, all of the oligomer peaks have
disappeared and the sample becomes very challenging to
electrospray into the gas-phase due to the high population of
insoluble amyloid fibrils present (data not shown). The short
lifetime of the oligomers observed suggest that they are either
on-pathway species, or that they are transient oﬀ-pathway
intermediates of fibrillation.
By contrast with the population of WT b2m oligomers,
the H51A higher order oligomers are still highly populated at
50% of the lag-phase (Fig. 3F). On extraction of the lowest
charge state ions corresponding to the WT b2m and H51A
monomer (i.e., 3+ ions) and oligomers (i.e., dimer 5+, trimer
7+, tetramer 9+, pentamer 11+) from the IMS driftscope plots,
the reproduced ESI mass spectra show clearly that a significantly
lower abundance of oligomers are present for WT b2m (Fig. 4A)
compared with the abundance of oligomers observed for the
H51A variant (Fig. 4B) at this time. In addition, a comparison
of the separated isobaric monomer 3+, dimer 6+ and trimer
9+ ions originating from H51A at m/z B4000 indicate that the
dimer and trimer are more abundant than the monomer in
contrast to the respective abundances of these three species
in the case of WT b2m at 50% lag-phase (Fig. S3, ESI†).
One possible explanation for this observation is that H51A
oligomers are less eﬃcient at converting into amyloid fibrils
compared with the WT b2m oligomers, and hence the H51A
oligomers accumulate during the lag-phase. Interestingly, the
IMS arrival time distributions of the H51A monomer 3+, dimer
5+, trimer 7+, tetramer 9+ and pentamer 11+ ions (i.e., the
lowest charge state ions in each case) are indistinguishable
(o2% diﬀerent) from those observed for the WT b2mmonomer
and oligomers indicating very similar CCSs (Fig. 4C and D).
Overall, the extended lag-time of H51A fibril formation is
accompanied by a higher population of oligomeric species that
persist for longer periods than their WT b2m counterparts, but
Fig. 3 ESI-MS mass spectra highlighting the oligomers present (m/z 2500–5000) for (A) WT b2m and (B) H51A, immediately after dilution into 100 mM
ammonium formate, pH 2.5. The charge states corresponding to the oligomers are highlighted: dimer (D), trimer (T), tetramer (Q) and pentamer (P). The
majority of the ions originating from the WT b2m and H51A monomers appear rm/z 2500 (Fig. S1, ESI†). No noticeable differences in the charge state
distributions for H51A and WT b2mmonomers were observed. ESI-IMS-MS driftscope plots of (C) WT b2m and (D) H51A immediately after dilution of the
proteins into the fibril-forming buffer (100 mM ammonium formate, pH 2.5) i.e., at 0% through their lag-phases of amyloid fibril formation; and (E) WT
b2m and (F) H51A at 50% through their respective lag-phases of amyloid fibril formation (monomer = red, dimer = orange, trimer = yellow, tetramer =
green, pentamer = blue, hexamer = purple).
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are indistinguishable based on their CCS values. This behaviour is
consistent with the presence of on-pathway, or transient oﬀ-pathway,
species that undergo relatively slow conversion to amyloid fibrils.
H51A forms more stable, less dynamic oligomers compared
with WT b2m
As the WT b2m and H51A oligomers showed no significant
diﬀerences in their ESI-IMS-MS CCS values indicating that they
cannot be distinguished in terms of their rotationally averaged
shapes, the stabilities and dynamics of these oligomers were
investigated further to determine whether other features could
explain the diﬀerences in fibril formation kinetics of the two
closely-related proteins. The dynamics of b2m oligomers
formed during fibrillogenesis in vitro can be determined using
subunit exchange experiments whereby 14N- and 15N-b2m oligomers
are mixed together and the rate of subunit exchange between
the two species is monitored using ESI-IMS-MS.27,28 If the
oligomers are highly dynamic entities and undergo rapid
exchange with each other, then mixed oligomers containing
both 14N- and 15N-protein will be observed using mass spectro-
metry. For example, three peaks in a 1 : 2 : 1 intensity ratio
would be observed for a rapidly exchanging protein dimer
corresponding to 14N:14N, 14N:15N and 15N:15N dimers. Similarly,
four peaks in a 1 : 3 : 3 : 1 ratio would be observed for a rapidly
exchanging trimer, and five peaks in a 1 : 4 : 6 : 4 : 1 ratio for a
rapidly exchanging tetramer (Fig. S4, ESI†). Alternatively, if the
oligomers are static entities, no exchange will occur and ions
corresponding to all 14N- and all 15N-proteins will be observed at
a 1 : 1 intensity ratio (Fig. S4, ESI†).
To determine whether the H51A oligomers are more kineti-
cally stable (less dynamic) than their WT b2m counterparts,
14N/15N subunit exchange experiments were investigated for
both WT b2m and H51A at 50% of their respective lag-phases.
Hence, 14N-WT b2m and
14N-H51A were incubated separately in
100 mM ammonium formate, pH 2.5 with agitation at 37 1C. At
times corresponding to 50% of their lag-phases, 15N-WT b2m or
15N-H51A, respectively (held on ice throughout and therefore
not aggregating), were added to their 14N-labelled counterpart
and any subunit exchange taking place was monitored using
ESI-MS over a 50 minute time-course at room temperature.
In all cases, the lag-phase was monitored in parallel using
ThT fluorescence, and the presence of fibrils at the end of the
lag-phase was confirmed by use of negative stain EM.
The extent of subunit exchange for 14N-WT b2m and
14N-H51A after 1 and 50 min of mixing with 15N-WT b2m
or 15N-H51A at 50% lag-phase, respectively, is shown in Fig. 5.
Fig. 4 ESI-IMS-MS mass spectra of the monomer (M) 3+ (red), dimer (D)
5+ (orange), trimer (T) 7+ (yellow), tetramer (Q) 9+ (green) and pentamer
(P) 11+ (blue) ions extracted from the IMS driftscope plot are shown for (A)
WT b2m and (B) H51A at 50% of their respective lag-phases together with
their individual ESI-IMS-MS arrival time distributions for (C) WT b2m
oligomers and (D) H51A oligomers.
Fig. 5 14N- and 15N-labelled oligomeric b2m subunit exchange experi-
ments illustrating the dimer (D) 7+, trimer (T) 10+ and 11+, and tetramer (Q)
13+ ions. Samples of 14N-WT b2m (A, C) or
14N-H51A (B, D) were mixed
with 15N-WT b2m or
15N-H51A monomer samples, respectively in a 1 : 1 (v/v)
ratio for 1 min (A, B) or 50 min (C, D) at 50% of the individual lag-phases for
the two proteins. Peaks corresponding to all 14N- and all 15N-oligomers are
shown in red, and peaks corresponding to mixed 14N/15N oligomers are
shown in blue.
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For WT b2m, the extent of
14N/15N-subunit exchange was
complete as soon as the 14N- and 15N-WT proteins were mixed
together, suggesting that all of the WT b2m oligomers are
dynamic in nature, in rapid equilibrium with exchanging
monomeric subunits (Fig. 5A and C). Interestingly, for the
H51A oligomers formed during the lag-phase, very little subunit
exchange occurred on initial mixing of the 14N- and 15N-H51A
proteins (Fig. 5B), suggesting that these oligomers are more stable
than the WT b2m oligomers, consistent with the results obtained
using analytical ultracentrifugation. Indeed, no noticeable exchange
was detected even after 50 minutes of incubation with 15N-H51A
(Fig. 5D). Importantly, the lack of significant subunit exchange
for the H51A oligomers supports our conclusion that the H51A
oligomers observed in the gas-phase are reflective of oligomers
present in solution and do not occur during the ESI process.
Indeed, if oligomer formation in H51A were to arise from non-
specific interactions occurring during the ESI process then complete
subunit exchange would be expected to occur instantaneously
upon mixing diﬀerently labelled protein subunits. The striking
diﬀerence in subunit exchange kinetics for H51A oligomers
compared with WT b2m is consistent with the increase
observed in the lag-time of fibril formation (Fig. 2). Although
the dynamics of the WT b2m and H51A oligomers diﬀer
considerably, their ESI-IMS-MS CCS values are very similar,
suggesting that any structural diﬀerences in their ternary or
quaternary structures that may aﬀect their kinetic stability do
not change the shape of the oligomers significantly.
The amino acid sequence corresponding to the D-strand of
native b2m has been implicated in fibril formation based on
structural,7,36,45 kinetic33 and peptide studies.31 Here we have
shown that although mutation of His51 to alanine decreases
the kinetics of fibril formation by increasing the lag-time, the
resulting fibrils have a morphology that is similar to that of
fibrils formed from WT b2m in vitro under the same solution
conditions. The increase in the lag-time of fibril formation
brought about by H51A is consistent with previous results on
the involvement of this residue in amyloid fibril formation.33,42
Detailed ESI-IMS-MS analyses of the H51A oligomeric inter-
mediates observed during the lag-time of fibril formation have
revealed for the first time significant diﬀerences in the populations
and subunit exchange dynamics of these oligomers compared with
the corresponding oligomers arising from theWT b2mprotein. Not
only are higher order oligomers observed for H51A, but all of the
oligomers detected are significantly more populated and have
increased stability compared with their WT counterparts.
One possible explanation for these diﬀerences is that the
H51A oligomers observed here may be oﬀ-pathway species, thus
slowing the rate of fibril formation by diverting H51Amonomers to
dead-end products. Alternatively the more stable, less dynamic
H51A oligomers could be slower at converting to the amyloidogenic
state compared with the oligomers formed from WT b2m (Fig. 6).
Interestingly, although ESI-IMS-MS was required to separate,
identify and estimate the populations of the individual oligo-
mers from within heterogeneous mixtures, any diﬀerences in
the conformational properties of the oligomers arising from the
two diﬀerent proteins were not evident from the ESI-IMS-MS
data, with the b2mWT and H51A oligomeric species having similar
CCS values indicative of shapes with similar overall dimensions.
Despite diﬀerences in the kinetics of amyloid fibril formation,
the fibril yield of H51A andWT b2m remain comparable as analysed
by SDS-PAGE analysis (Fig. 2E). This suggests that although
more stable oligomers form extremely rapidly in the case of
H51A compared with WT b2m, at the end of the lag-time and
exponential growth phase these oligomers are all converted to
fibrils with the same morphology as WT b2m (Fig. 2B).
Conclusions
Numerous studies have investigated the eﬀects of small mole-
cule binding to amyloid-forming protein monomers,45–48 in
addition to probing the effect of point mutations in the starting
monomer sequence on amyloid fibril formation.9,49 However,
to our knowledge, this is the first detailed study reporting on the
correlation between the lag-time and the population and kinetic
stability of oligomeric species. Thus, the H51A oligomers become
kinetically trapped, increasing in population and converting
slowly into amyloid fibrils. These results illustrate the importance
of H51 in b2m fibril formation at low pH. They also highlight the
power of ESI-IMS-MS combined with subunit exchange dynamics
in characterising the behaviour of individual oligomeric inter-
mediates from a heterogeneous ensemble in real-time, revealing
detailed insights into the nature and potential role of oligomeric
intermediates in amyloid fibril formation.
Acknowledgements
ACL was funded by a BBSRC CASE PhD studentship in collabora-
tion with Dr John Hoyes and DrMikeMorris, Micromass UK Ltd/
Waters Corpn, Manchester, UK (BB/526502/1). CLP is funded
by the Wellcome Trust (WT092896MA) and CAS by the BBSRC
(BB/H024875/1). We acknowledge the BBSRC for funding the
Fig. 6 Model of b2m amyloid fibril formation whereby WT b2m unfolds at
low pH and forms dynamic oligomers that reach a critical nucleus and then
convert rapidly into mature amyloid fibrils. In the case of H51A, the point
mutation causes oligomers to form rapidly, although these more abun-
dant, highly populated and kinetically stable oligomers are significantly
more stable and less dynamic than the WT b2m oligomers and thus slower
at converting into the critical nucleus that results in an increased lag-time
of amyloid fibril formation.
Molecular BioSystems Paper
This journal is©The Royal Society of Chemistry 2014 Mol. BioSyst., 2014, 10, 412--420 | 419
purchase of the Synapt HDMS mass spectrometer (BB/E012558/
1). We also thank Dr Katy Routledge for the expression and
purification of the 14N-H51A protein used throughout these
experiments and all members of the Ashcroft and Radford
groups for useful discussions.
References
1 C. M. Dobson, Protein folding and misfolding, Nature, 2003,
426, 884–890.
2 F. U. Hartl, Molecular chaperones in cellular protein fold-
ing, Nature, 1996, 381, 571–580.
3 T. Eichner and S. E. Radford, A diversity of assembly
mechanisms of a generic amyloid fold, Mol. Cell, 2011, 43,
8–18.
4 F. Chiti and C. M. Dobson, Protein misfolding, functional
amyloid, and human disease, Annual Review of Biochemistry,
Annual Reviews, Palo Alto, 2006, pp. 333–366.
5 F. Gejyo, T. Yamada, S. Odani, Y. Nakagawa, M. Arakawa,
T. Kunitomo, H. Kataoka, M. Suzuki, Y. Hirasawa,
T. Shirahama, A. S. Cohen and K. Schmid, A new form of
amyloid protein associated with chronic-hemodialysis was
identified as beta 2-microglobulin, Biochem. Biophys. Res.
Commun., 1985, 129, 701–706.
6 T. Eichner and S. E. Radford, Understanding the complex
mechanisms of beta 2-microglobulin amyloid assembly,
FEBS J., 2011, 278, 3868–3883.
7 C. H. Trinh, D. P. Smith, A. P. Kalverda, S. E. V. Phillips and
S. E. Radford, Crystal structure of monomeric human beta-
2-microglobulin reveals clues to its amyloidogenic proper-
ties, Proc. Natl. Acad. Sci. U. S. A., 2002, 99, 9771–9776.
8 T. Eichner and S. E. Radford, A generic mechanism of
beta(2)-Microglobulin amyloid assembly at neutral pH
involving a specific proline switch, J. Mol. Biol., 2009, 386,
1312–1326.
9 C. Santambrogio, S. Ricagno, M. Colombo, A. Barbiroli,
F. Bonomi, V. Bellotti, M. Bolognesi and R. Grandori, DE-loop
mutations aﬀect beta 2-microglobulin stability, oligomerization,
and the low-pH unfolded form, Protein Sci., 2010, 19,
1386–1394.
10 M. F. Calabrese and A. D. Miranker, Metal binding sheds
light on mechanisms of amyloid assembly, Prion, 2009, 3,
1–4.
11 N. M. Kad, N. H. Thomson, D. P. Smith, D. A. Smith and
S. E. Radford, Beta(2)-microglobulin and its deamidated
variant, N17D form amyloid fibrils with a range of morphol-
ogies in vitro, J. Mol. Biol., 2001, 313, 559–571.
12 G. W. Platt, K. E. Routledge, S. W. Homans and
S. E. Radford, Fibril growth kinetics reveal a region of
beta(2)-microglobulin important for nucleation and elonga-
tion of aggregation, J. Mol. Biol., 2008, 378, 251–263.
13 W. S. Gosal, I. J. Morten, E. W. Hewitt, D. A. Smith,
N. H. Thomson and S. E. Radford, Competing pathways
determine fibril morphology in the self-assembly of beta(2)-
microglobulin into amyloid, J. Mol. Biol., 2005, 351, 850–864.
14 S. L. Myers, S. Jones, T. R. Jahn, I. J. Morten, G. A. Tennent,
E. W. Hewitt and S. E. Radford, A systematic study of
the eﬀect of physiological factors on beta 2-microglobulin
amyloid formation at neutral pH, Biochemistry, 2006, 45,
2311–2321.
15 D. P. Smith, S. Jones, L. C. Serpell, M. Sunde and
S. E. Radford, A systematic investigation into the eﬀect of
protein destabilisation on beta 2-microglobulin amyloid
formation, J. Mol. Biol., 2003, 330, 943–954.
16 C. L. Ladner, M. Chen, D. P. Smith, G. W. Platt, S. E. Radford
and R. Langen, Stacked sets of parallel, in-register beta-
strands of beta(2)-microglobulin in amyloid fibrils revealed
by site-directed spin labeling and chemical labeling, J. Biol.
Chem., 2010, 285, 17137–17147.
17 G. T. Debelouchina, G. W. Platt, M. J. Bayro, S. E. Radford
and R. G. Griﬃn, Intermolecular alignment in beta(2)-
microglobulin amyloid fibrils, J. Am. Chem. Soc., 2010,
132, 17077–17079.
18 H. E. White, J. L. Hodgkinson, T. R. Jahn, S. Cohen-Krausz,
W. S. Gosal, S. Muller, E. V. Orlova, S. E. Radford and
H. R. Saibil, Globular tetramers of beta(2)-microglobulin
assemble into elaborate amyloid fibrils, J. Mol. Biol., 2009,
389, 48–57.
19 A. E. Ashcroft, Mass spectrometry and the amyloid problem-
how far can we go in the gas phase?, J. Am. Soc. Mass
Spectrom., 2010, 21, 1087–1096.
20 D. M. Williams and T. L. Pukala, Novel insights into protein
misfolding diseases revealed by ion mobility-mass spectro-
metry, Mass Spectrom. Rev., 2013, 32, 169–187.
21 L. F. Lue, Y. M. Kuo, A. E. Roher, L. Brachova, Y. Shen,
L. Sue, T. Beach, J. H. Kurth, R. E. Rydel and J. Rogers,
Soluble amyloid beta peptide concentration as a predictor
of synaptic change in Alzheimer’s disease, Am. J. Pathol.,
1999, 155, 853–862.
22 J. Wang, D. W. Dickson, J. Q. Trojanowski and V. M. Y. Lee,
The levels of soluble versus insoluble brain A-beta distin-
guish Alzheimer’s disease from normal and pathologic
aging, Exp. Neurol., 1999, 158, 328–337.
23 J. L. Tomic, A. Pensalfini, E. Head and C. G. Glabe, Soluble
fibrillar oligomer levels are elevated in Alzheimer’s disease
brain and correlate with cognitive dysfunction, Neurobiol.
Dis., 2009, 35, 352–358.
24 B. Winner, R. Jappelli, S. K. Maji, P. A. Desplats, L. Boyer,
S. Aigner, C. Hetzer, T. Loher, M. Vilar, S. Campionic,
C. Tzitzilonis, A. Soragni, S. Jessberger, H. Mira,
A. Consiglio, E. Pham, E. Masliah, F. G. Gage and R. Riek,
In vivo demonstration that alpha-synuclein oligomers are
toxic, Proc. Natl. Acad. Sci. U. S. A., 2011, 108, 4194–4199.
25 N. Reixach, S. Deechongkit, X. Jiang, J. W. Kelly and
J. N. Buxbaum, Tissue damage in the amyloidoses: Trans-
thyretin monomers and non-native oligomers are the major
cytotoxic species in tissue culture, Proc. Natl. Acad. Sci.
U. S. A., 2004, 101, 2817–2822.
26 M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli,
J. S. Zurdo, N. Taddei, G. Ramponi, C. M. Dobson and
M. Stefani, Inherent toxicity of aggregates implies a
Paper Molecular BioSystems
420 | Mol. BioSyst., 2014, 10, 412--420 This journal is©The Royal Society of Chemistry 2014
common mechanism for protein misfolding diseases,
Nature, 2002, 416, 507–511.
27 D. P. Smith, S. E. Radford and A. E. Ashcroft, Elongated
oligomers in beta(2)-microglobulin amyloid assembly
revealed by ion mobility spectrometry-mass spectrometry,
Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 6794–6798.
28 D. P. Smith, L. A. Woods, S. E. Radford and A. E. Ashcroft,
Structure and dynamics of oligomeric intermediates in beta(2)-
microglobulin self-assembly, Biophys. J., 2011, 101, 1238–1247.
29 G. Esposito, S. Ricagno, A. Corazza, E. Rennella, D. Gumral,
M. C. Mimmi, E. Betto, C. E. M. Pucillo, F. Fogolari, P. Viglino,
S. Raimondi, S. Giorgetti, B. Bolognesi, G. Merlini, M. Stoppini,
M. Bolognesi and V. Bellotti, Aggregation properties the con-
trolling roles of Trp60 and Trp95 in beta(2)-microglobulin
function, folding and amyloid aggregation properties, J. Mol.
Biol., 2008, 378, 887–897.
30 J. P. Hodkinson, T. R. Jahn, S. E. Radford and A. E. Ashcroft,
HDX-ESI-MS reveals enhanced conformational dynamics of
the amyloidogenic protein beta(2)-microglobulin upon
release from the MHC-1, J. Am. Soc. Mass Spectrom., 2009,
20, 278–286.
31 C. Liu, M. Zhao, L. Jiang, P. Cheng, J. Park, M. R. Sawaya,
A. Pensalfinic, D. Goud, A. J. Berk, C. G. Glabe, J. Nowick
and D. Eisenberg, Out-of-register b-sheets suggest a pathway
to toxic amyloid aggregates, Proc. Natl. Acad. Sci. U. S. A.,
2012, 109, 20913–20918.
32 S. Ricagno, M. Colombo, M. de Rosa, E. Sangiovanni,
S. Giorgetti, S. Raimondi, V. Bellotti and M. Bolognesi,
DE loop mutations aﬀect beta 2-microglobulin stability
and amyloid aggregation, Biochem. Biophys. Res. Commun.,
2008, 377, 146–150.
33 K. E. Routledge, G. G. Tartaglia, G. W. Platt, M. Vendrusco
and S. E. Radford, Competition between intramolecular and
intermolecular interactions in an amyloid-forming protein,
J. Mol. Biol., 2009, 389, 776–786.
34 P. Hortschansky, V. Schroeckh, T. Christopeit, G. Zandomeneghi
and M. Fandrich, The aggregation kinetics of Alzheimer’s beta-
amyloid peptide is controlled by stochastic nucleation, Protein
Sci., 2005, 14, 1753–1759.
35 M. J. Shields, N. Assefi, W. Hodgson, E. J. Kim and
R. K. Ribaudo, Characterization of the interactions between
MHC class I subunits: A systematic approach for the engi-
neering of higher aﬃnity variants of beta(2)-microglobulin,
J. Immunol., 1998, 160, 2297–2307.
36 S. Azinas, M. Colombo, A. Barbiroli, C. Santambrogio,
S. Giorgetti, S. Raimondi, F. Bonomi, R. Grandori,
V. Bellotti, S. Ricagno and M. Bolognesi, D-strand perturba-
tion and amyloid propensity in beta-2 microglobulin, FEBS
J., 2011, 278, 2349–2358.
37 M. Okon, P. Bray and D. Vucelic, H-1-NMR assignments and
secondary structure of human beta-2-microglobulin in
solution, Biochemistry, 1992, 31, 8906–8915.
38 G. Verdone, A. Corazza, P. Viglino, F. Pettirossi, S. Giorgetti,
P. Mangione, A. Andreola, M. Stoppini, V. Bellotti and
G. Esposito, The solution structure of human beta
2-microglobulin reveals the prodromes of its amyloid
transition, Protein Sci., 2002, 11, 487–499.
39 S. Park and J. G. Saven, Simulation of pH-dependent
edge strand rearrangement in human beta 2-microglobulin,
Protein Sci., 2006, 15, 200–207.
40 V. L. Mendoza, K. Antwi, M. A. Baron-Rodriguez, C. Blanco
and R. W. Vachet, Structure of the pre-amyloid dimer of
beta-2-microglobulin from covalent labeling and mass spec-
trometry, Biochemistry, 2010, 49, 1522–1532.
41 V. L. Mendoza, M. A. Baron-Rodriguez, C. Blanco and
R. W. Vachet, Structural insights into the pre-amyloid
tetramer of beta-2-microglobulin from covalent labeling
and mass spectrometry, Biochemistry, 2011, 50, 6711–6722.
42 T. Chiba, Y. Hagihara, T. Higurashi, K. Hasegawa, H. Naiki
and Y. Goto, Amyloid fibril formation in the context of full-
length protein - eﬀects of proline mutations on the amyloid
fibril formation of beta(2)-microglobulin, J. Biol. Chem.,
2003, 278, 47016–47024.
43 P. Schuck, Size-distribution analysis of macromolecules by
sedimentation velocity ultracentrifugation and Lamm equa-
tion modelling, Biophys. J., 2000, 78, 1606–1619.
44 A. M. Smith, T. R. Jahn, A. E. Ashcroft and S. E. Radford,
Direct observation of oligomeric species formed in the early
stages of amyloid fibril formation using electrospray
ionisation-mass spectrometry, J. Mol. Biol., 2006, 364, 9–19.
45 M. Colombo, M. de Rosa, V. Bellotti, S. Ricagno and
M. Bolognesi, A recurrent D-strand association interface is
observed in beta 2-microglobulin oligomers, FEBS J., 2012,
279, 1131–1143.
46 L. A. Woods, G. W. Platt, A. L. Hellewell, E. W. Hewitt,
S. W. Homans, A. E. Ashcroft and S. E. Radford, Ligand
binding to distinct states diverts aggregation of an amyloid-
forming protein, Nat. Chem. Biol., 2011, 7, 730–739.
47 D. E. Ehrnhoefer, J. Bieschke, A. Boeddrich, M. Herbst,
L. Masino, R. Lurz, S. Engemann, A. Pastore and
E. E. Wanker, EGCG redirects amyloidogenic polypeptides
into unstructured, oﬀ-pathway oligomers, Nat. Struct. Mol.
Biol., 2008, 15, 558–566.
48 S. J. Hyung, A. S. DeToma, J. R. Brender, S. Lee,
S. Vivekanandan, A. Kochi, J. S. Choi, A. Ramamoorthy,
B. T. Ruotolo and M. H. Lim, Insights into anti-
amyloidogenic properties of the green tea extract
(-)-epigallocatechin-3-gallate toward metal-associated
amyloid-beta species, Proc. Natl. Acad. Sci. U. S. A., 2013,
110, 3743–3748.
49 M. M. Gessel, S. Bernstein, M. Kemper, D. B. Teplow and
M. T. Bowers, Familial Alzheimer’s disease mutations dif-
ferentially alter amyloid beta-protein oligomerization, ACS
Chem. Neurosci., 2012, 3, 909–918.
Molecular BioSystems Paper
